The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Drospirenone (Slynd®) has been rejected for use as a progestogen only contraceptive. The manufacturer failed to make a submission for this indication.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.